Original ArticleAtopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study
Cited by (0)
Disclosures: Dr Silverberg has acted as a consultant for and/or received grants/honoraria from AbbVie Inc, AnaptysBio, Inc, Asana Biosciences, LLC, Eli Lilly and Company, Galderma Research & Development, LLC, GlaxoSmithKline plc, Glenmark Generics, Inc, Kiniksa Pharmaceuticals, Ltd, LEO Pharma A/S, MedImmune, LLC, Menlo Therapeutics Inc, Pfizer Inc, PuriCore, Inc, Regeneron Pharmaceuticals Inc, and Sanofi. Dr Barbarot has received research grants from Pierre Fabre Laboratory and Fondation pour la dermatite atopique; personal fees from Bioderma Laboratories, Laboratoire La Roche Posay, Sanofi Genzyme, Novalac, and Ferring Pharmaceuticals; and nonfinancial support from AbbVie Inc, Novartis AG, and Janssen Pharmaceutica. Dr Simpson has received grants/research support from Amgen Inc, Celgene Corporation, Chugai Pharmaceutical Co, Ltd, Galderma, Genentech, Inc, MedImmune, LLC, Sanofi/Regeneron Pharmaceuticals Inc, Tioga Research, Vanda Pharmaceuticals Inc, and Eli Lilly and Company and is a consultant for Anacor Pharmaceuticals Inc, Celgene Corporation, Galderma, Genentech, Inc, Medicis Pharmaceutical Corporation, Sanofi/Regeneron Pharmaceuticals Inc, and Merck. Dr Weidinger is a coprincipal investigator of the German Atopic Dermatitis Registry TREATgermany; has received institutional research grants from Novartis AG, Pfizer Inc, L‘Oréal and LEO Pharma A/S; has performed consultancies for Sanofi Genzyme, Regeneron Pharmaceuticals Inc, LEO Pharma A/S, Incyte Corp, and Novartis AG; has lectured at educational events sponsored by Sanofi Genzyme, Regeneron Pharmaceuticals Inc, LEO Pharma A/S, AbbVie Inc, and Galderma; and is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for, for example, the treatment of psoriasis and atopic eczema. Dr Mina-Osorio was an employee of and stockholder in Regeneron Pharmaceuticals Inc at the time the study was conducted and is a current employee of Aurinia Pharmaceuticals Inc. Dr Gadkari was an employee of and stockholder in Regeneron Pharmaceuticals Inc at the time of the study and is a current employee of Boehringer Ingelheim Corporation. Dr Rossi and Dr Eckert are employees of and stockholders in Sanofi. Dr Fenton was an employee of Sanofi at the time of the study and is currently employed at Syneos Health. Dr Guillemin was an employee of Sanofi at the time of the study. Dr Saba, Mr Auziere, and Ms Brignoli are employees of Kantar Health Division, who received funding from Sanofi to conduct the study.
Funding: This study was funded by Sanofi and Regeneron Pharmaceuticals Inc.